Pages that link to "Q33886341"
Jump to navigation
Jump to search
The following pages link to ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling (Q33886341):
Displaying 50 items.
- Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members (Q21195197) (← links)
- The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy (Q21284978) (← links)
- Copine-III interacts with ErbB2 and promotes tumor cell migration (Q22001536) (← links)
- Cripto: a novel epidermal growth factor (EGF)-related peptide in mammary gland development and neoplasia (Q22009058) (← links)
- ErbB2 and ErbB3 receptors mediate inhibition of calcium-dependent chloride secretion in colonic epithelial cells (Q22010784) (← links)
- Dominance of ErbB-1 heterodimers in lung epithelial cells overexpressing ErbB-2. Both ErbB-1 and ErbB-2 contribute significantly to tumorigenicity (Q22010838) (← links)
- Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells (Q22254244) (← links)
- Overexpression of ErbB2 enhances ethanol-stimulated intracellular signaling and invasion of human mammary epithelial and breast cancer cells in vitro (Q23911300) (← links)
- Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association (Q24297029) (← links)
- HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors (Q24297102) (← links)
- Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains (Q24307661) (← links)
- IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistance (Q24309891) (← links)
- The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis (Q24312466) (← links)
- Flow cytometric in situ proximity ligation analyses of protein interactions and post-translational modification of the epidermal growth factor receptor family (Q24319831) (← links)
- The atypical histone macroH2A1.2 interacts with HER-2 protein in cancer cells (Q24322930) (← links)
- Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity (Q24324102) (← links)
- Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay (Q24337937) (← links)
- ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner (Q24522643) (← links)
- Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors (Q24532786) (← links)
- Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4. (Q24537669) (← links)
- Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2 (Q24538180) (← links)
- Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain (Q24551173) (← links)
- Molecular biology of lung cancer (Q24606677) (← links)
- Dual Inhibitor AEE788 Reduces Tumor Growth in Preclinical Models of Medulloblastoma (Q24615472) (← links)
- Phosphotyrosine interactome of the ErbB-receptor kinase family (Q24672516) (← links)
- Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor tyrosine kinase ErbB-2 (Q24676439) (← links)
- The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation (Q24678674) (← links)
- Neuregulin3 alters cell fate in the epidermis and mammary gland (Q24681926) (← links)
- ErbB receptors: from oncogenes to targeted cancer therapies (Q24683709) (← links)
- Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer (Q24795614) (← links)
- Tyrosine kinase signalling in breast cancer (Q24802908) (← links)
- Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells. (Q24813543) (← links)
- HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells (Q25257668) (← links)
- Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine (Q26747729) (← links)
- Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going (Q26750740) (← links)
- Cytokines in cancer drug resistance: Cues to new therapeutic strategies (Q26753299) (← links)
- Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review (Q26777733) (← links)
- NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy (Q26797345) (← links)
- Analysis of different HER-2 mutations in breast cancer progression and drug resistance (Q26797471) (← links)
- HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies (Q26822730) (← links)
- Targeted therapy for HER2 positive breast cancer (Q26830496) (← links)
- Targeting of erbB3 receptor to overcome resistance in cancer treatment (Q26864668) (← links)
- Systemic and targeted therapies for early-stage lung cancer (Q26865490) (← links)
- Pulmonary epithelial barrier function: some new players and mechanisms (Q26865861) (← links)
- Profile of neratinib and its potential in the treatment of breast cancer (Q27012540) (← links)
- Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities (Q27027433) (← links)
- ErbB2-dependent chemotaxis requires microtubule capture and stabilization coordinated by distinct signaling pathways (Q27317093) (← links)
- Solution structure of betacellulin, a new member of EGF-family ligands (Q27639195) (← links)
- The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors (Q27640631) (← links)
- An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin (Q27679463) (← links)